News
An added benefit of the new combination compared to the triple combination of bevacizumab, cisplatin and pemetrexed is also not proven - regardless of tumour histology. Malignant pleural ...
An added benefit of the new combination compared to the triple combination of bevacizumab, cisplatin and pemetrexed is also not proven—regardless of tumor histology. Malignant pleural ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback